Trading Halt Update: Novitas Proposes Changes to LCD
MKTUPDTE
Fri, Jul 29 2022 12:16 pm
29 July 2022
TRADING HALT UPDATE: NOVITAS PROPOSES CHANGES TO LCD
DUNEDIN, New Zealand – Cancer diagnostics company Pacific Edge (NZX, ASX: PEB) became aware overnight (NZT) of the inclusion of Cxbladder CPT codes in a draft proposal for a different approach to determine which cancer biomarker tests are eligible for reimbursement by Novitas.
The publication of the proposed approach for Genetic Testing in Oncology is set out in a draft Local Coverage Determination (LCD, DL39365) and a draft Local Coverage Article (LCA, DA59125).
Pacific Edge will provide its shareholders with further clarification of the implications for Pacific Edge once it has received advice from its US legal team and other advisors prior to lifting the current trading halt.
Released for and on behalf of Pacific Edge by Grant Gibson Chief Financial Officer.
For more information:
Dr Peter Meintjes
Chief Executive
Pacific Edge
P: +64 22 032 1263
Announcement PDF
Markets News
Markets
Fletcher dodges product recall in upbeat end to August for NZX 50
The S&P/NZX 50 Index rose 97.07 points, or 0.8%, to 12,447.68.
Markets
Fletcher Building expects $168m hit from leaky pipes response
Fletcher Building subsidiary Iplex Australia to cover 80% of repair costs.
Markets
Ritchies posts $17m annual net loss
The bus operator's net loss widened from $8m to $17m in the year to March 31.
